When does osimertinib’s patent protection expire in Taiwan?
Osimertinib (brand: Tagrisso) patent timelines in Taiwan depend on which specific patent family and protection type you mean (for example, the original compound patent versus later process, formulation, or “second medical use” patents). Patent expiry dates also differ from any marketing authorization milestones.
Because the exact Taiwan patent numbers and listed expiry dates are not provided here, there is no single definitive “osimertinib patent expires on [date] in Taiwan” answer that can be stated reliably from the information available.
What’s usually protected by osimertinib patents in Taiwan, and why dates differ?
In practice, Taiwan litigation and exclusivity outcomes often hinge on:
- Primary (compound) patents covering the active ingredient.
- Additional patents later in the lifecycle (manufacturing/process, specific crystalline form/solid-state, or other dependent claims).
- Whether the “Orange Book”-style listing of patents tied to the drug is complete and which patents are asserted.
This means even if one patent expires, other listed patents may still block full generic entry.
How can you find the exact Taiwan expiration date for osimertinib?
To get the exact expiry date(s) in Taiwan, you need the specific Taiwan patent publication/registration number(s) tied to osimertinib and the claim type. The most reliable way is to:
1. Identify the Taiwan patents listed/associated with Tagrisso (osimertinib).
2. Check each patent’s filing and term rules to calculate its scheduled expiry date.
3. Note that any regulatory-linked exclusivity (if applicable) and any court actions can affect actual market entry timing even if a patent’s scheduled term ends.
If you share the Taiwan patent number(s) you’re looking at (or a link/name of the patent in a database), I can help interpret what the expiry date means and which patents likely matter for generic timing.
Does generic entry in Taiwan depend on patent expiry or regulatory exclusivity?
Generic or biosimilar-like entry (for small-molecule generics, “generic entry” in the regulatory sense) typically depends on whether any enforceable patents still cover the product in Taiwan. So, actual timing can differ from the earliest scheduled expiry date if other patents remain in force or are successfully asserted.
If you tell me whether you care about “earliest possible generic entry” versus “earliest compound patent expiry,” I can tailor the answer accordingly.
What to check next if you’re tracking osimertinib vs generics in Taiwan
People typically want one of these:
- The earliest expiry of the core compound patent in Taiwan.
- The last expiry among all relevant Taiwan-listed patents that block generics.
- Whether there are ongoing patent disputes that extend practical exclusivity.
If you provide any of the following, I can narrow it down: Tagrisso/Taiwan patent IDs, a source you’re using (database or document), or the specific wording of the patent grant/publication.
Sources
I didn’t cite any sources because no Taiwan-specific patent publication numbers, court filings, or database links were provided in your question.